In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2

Remdesivir (RDV), a broadly acting nucleoside analogue, is the only FDA approved small molecule antiviral for the treatment of COVID-19 patients. To date, there are no reports identifying SARS-CoV-2 RDV resistance in patients, animal models or in vitro. Here, we selected drug-resistant viral populat...

Descripción completa

Detalles Bibliográficos
Autores principales: Szemiel, Agnieszka M., Merits, Andres, Orton, Richard J., MacLean, Oscar A., Pinto, Rute Maria, Wickenhagen, Arthur, Lieber, Gauthier, Turnbull, Matthew L., Wang, Sainan, Furnon, Wilhelm, Suarez, Nicolas M., Mair, Daniel, da Silva Filipe, Ana, Willett, Brian J., Wilson, Sam J., Patel, Arvind H., Thomson, Emma C., Palmarini, Massimo, Kohl, Alain, Stewart, Meredith E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496873/
https://www.ncbi.nlm.nih.gov/pubmed/34534263
http://dx.doi.org/10.1371/journal.ppat.1009929

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496873/
https://www.ncbi.nlm.nih.gov/pubmed/34534263
http://dx.doi.org/10.1371/journal.ppat.1009929

Ejemplares similares